A 3-Arm Randomized Phase II Trial Evaluating Single Agent and Combined Efficacy of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Everolimus (Primary) ; Pasireotide (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 13 Apr 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 13 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
- 13 Apr 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Apr 2017.